CHICAGO — The growing abundance of technology options for better diabetes management and the trend away from HbA1c as the only evaluation metric for the condition are important parallel phenomena, according to a speaker at the Cardiometabolic Health Congress. Anne Peters, MD, director of USC clinical diabetes programs and professor of clinical medicine at the Keck School of Medicine
Healio: ‘Digiceuticals,’ new CGM devices, HbA1c alternatives transform diabetes management